Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion type Assertion NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_head.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion description "[At higher doses, differences between the TP53-mutated lines were observed with TOV-112D being less sensitive to cisplatin than OV-90 that also harbors a CDNK2A mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_provenance.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion evidence source_evidence_literature NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_provenance.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion SIO_000772 15258697 NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_provenance.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion wasDerivedFrom befree-20150227 NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_provenance.
- NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_assertion wasGeneratedBy ECO_0000203 NP754635.RAd3Cf86P5z4ehaBP1oI0rxWpEFRobhdCCuAiwxe_-JgE130_provenance.